<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313702</url>
  </required_header>
  <id_info>
    <org_study_id>IEP001/2011</org_study_id>
    <nct_id>NCT01313702</nct_id>
  </id_info>
  <brief_title>Single Pill to Avert Cardiovascular Events</brief_title>
  <acronym>SPACE</acronym>
  <official_title>Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a polipill improved the compliance with
      treatment compared to usual care that use two or more drugs,in patients at high
      cardiovascular risk or previous cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compliance with treatment</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changed in blood pressure</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in LDL-cholesterol levels</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the main reason for non compliance with treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of poli pill measures by laboratorial tests</measure>
    <time_frame>18 months</time_frame>
    <description>hemogram and blood platelets count, liver function tests (ALT, AST), renal function tests (creatinine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combined outcome</measure>
    <time_frame>18 months</time_frame>
    <description>compound of cardiovascular and total mortality, major cardiovascular events and cholesterol levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>polipillV1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polipillV2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polipillV1</intervention_name>
    <description>polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg</description>
    <arm_group_label>polipillV1</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polipillV2</intervention_name>
    <description>Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.</description>
    <arm_group_label>polipillV2</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual care</intervention_name>
    <description>the drugs used in clinical practice, defined by physician</description>
    <arm_group_label>usual care</arm_group_label>
    <other_name>lisinopril</other_name>
    <other_name>simvastatin</other_name>
    <other_name>atenolol</other_name>
    <other_name>hidrochlorotiazide</other_name>
    <other_name>acetylsalicilic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age ≥ 18 years old;

          -  Patient that could written informed consent;

          -  Patient with current atherothrombotic cardiovascular disease or at high cardiovascular
             risk, defined as:

          -  Patients with previous Coronary Artery Disease (miocardial Infarction, estable or
             instable angina pectoris or coronary revascularization procedures);

          -  Patients with previous miocardial Infarction, defined as medical registry (with
             documentation of at least 2 criterias: clinical symptoms,patological electrocardiogram
             and elevation of cardiac enzymes- CK-MB and/or troponin);

          -  Patients with previous brain ischemia (stroke or transient ischemic attack)

          -  Patients with confirmed previous peripheral arterial disease (Coronary Artery Bypass
             procedures or angioplasty or amputation due peripheral arterial disease)

          -  Patients with no established cardiovascular disease but at high cardiovascular risk,
             defined as 15% or more in 5 years (using the Anderson Framingham scale, 1991)

        Exclusion Criteria:

          -  contraindication for any of the polipill

          -  If the physician opinion is that terapeutical change could harm the patient (for
             example, heart failure, need of high beta blocker dose for treatment angina symptons
             and for the atrial fibrillation rhythm,severe hypertension [degree 3], malignant
             hypertension or renal insufficiency

          -  Acute clinical conditions/ surgeries

          -  Psychiatry clinical conditions(for example, schizophrenia, serious depression)

          -  pregnant or lactation women

          -  women at fertile period mulheres not using effective contraceptive methods (oral
             contraceptive, condom, intrauterine device)

          -  liver siseases (AST/ALT/FA upon 3 x normal superior limits / bilirrubin upon 1,5 X
             normal superior limits / diagnosed Liver Cirrhosis

          -  Renal disfunction (any laboratorial exams upon 3 x normal superior limits)

          -  Previous participation on other clinical trial

          -  The participant is unable or refuse to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otavio Berwanger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto de Ensino e Pesquisa - IEP - HCor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Otavio Berwanger, PhD</last_name>
    <phone>+55 11 30536611</phone>
    <phone_ext>8203</phone_ext>
    <email>oberwanger@hcor.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa - IEP - HCor</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04005-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Otavio Berwanger, PhD</last_name>
      <phone>+55 11 30536611</phone>
      <phone_ext>8203</phone_ext>
      <email>oberwanger@hcor.com.br</email>
    </contact>
    <investigator>
      <last_name>Otavio Berwanger, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polypill, compliance, cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

